Study to Investigate effect of Omega-3 on Alzheimer’s

Fish is rated high on the heart-healthy diet of many nutritionists. Their point has gained more ground now, since studies have revealed that certain fish, human breast milk, and algae contain omega-3 fatty acids, which are beneficial for the brain and may lower the risk of developing Alzheimer’s disease.

Researchers are now involved in conducting a clinical trial to test if the omega-3 fatty acid docosahexaenoic acid (DHA) can inhibit the progression of Alzheimer’s disease.

Primarily, the studies are trying to evaluate if consuming DHA for a long period can slow down both cognitive and functional decline in patients suffering from mild to moderate Alzheimer’s disease.

The study is conducted by Sun Health Research Institute and Banner Alzheimer’s Institute, supported by the National Institute on Aging, and is currently seeking participants.

Simvastatin Halves Alzheimer’s and Parkinson’s Risks

The statin, Simvastatin, has been found to cut the risk of developing Alzheimer’s and Parkinson’s disease by 50 percent.

Researchers at Boston University School of Medicine analyzed diagnostic, pharmaceutical, and demographic data of around 4.5 million people. This data was collected from various medical centers across the country.
To analyze the effects, researchers used three different models and examined the effects of the statins simvastatin, lovastatin, and atorvastatin on people.

They found a considerable decline in the occurrence of Alzheimer’s as well as Parkinson’s disease in people on simvastatin in each of the three models.
It is speculated that simvastatin is more beneficial as it possesses both high potency and the capability to enter the brain.

Source: Boston University 

Novartis Receives FDA Approval for Exelon Skin Patch to Treat Alzheimer’s Disease

Swiss drug maker Novartis AG Monday said it received approval from the U.S. Food and Drug Administration for its Exelon skin patch for the treatment of Alzheimer’s disease.

Novartis, based in Basel, said this was the first approval world-wide for the patch, which delivers the medicine for mild to moderate Alzheimer’s disease patients through a skin patch instead of an oral capsule.